Immune Netw, 2026, 26(2):e1

In Search of Adaptive-Like Features of NK Cells Co-Expressing NKG2C and NKG2A

Adaptive-like functions of NK cells have been extensively studied in the context of human cytomegalovirus (HCMV) infection, particularly for NKG2C NK cells. The NKG2A inhibitory and the NKG2C activating receptors share a common ligand, the HLA-E molecule, and can be co-expressed in a unique NK cell subset. However, key characteristics and memory response capacity of this subset remain unclear. We analyzed the proliferative responses, functional attributes and transcriptional signatures of NKG2CNKG2A subsets within CD57 and CD57 fractions of peripheral blood CD56NK cells by comparing them with NKG2A counterparts. Double-positive NK cells displayed a less mature phenotype, increased MHC-II and exhibited transcriptome profile indicating enhanced adhesion/migration capacities with no difference in adaptive state associated genes expression. These cells showed enhanced proliferation compared to NKG2A cells, which was not reduced upon interaction with HLA-E presenting the HCMV (VMAPRTLFL, LFL) peptide. CD57NKG2CNKG2A subset showed enhanced antibody-dependent IFNγ production. Expanded upon LFL stimulation this subset again exhibited enhanced IFNγ production capacity along with peptide-specific mRNA expression profile, demonstrating an adaptive-like response. These results provide additional insight into the diversity of HCMV-specific NK cell subsets, highlighting NKG2ANKG2C NK cells' immunotherapeutical potential.

IBCH: 12581
Ссылка на статью в журнале: https://doi.org/10.4110/in.2026.26.e1
Кол-во цитирований на 05.2026: 0
Данные статьи проверены модераторами 2026-09-27

Список научных проектов, где отмечена публикация

  1. -Противовирусная роль NK-клеток при инфекциях CMV и SARS-CoV-2 и подходы к использованию противовирусного потенциала NK-клеток в терапии (January 6, 2022 — December 31, 2024). Kovalenko E.I.. Grant, RSF.
  2. Novel approaches for studying the recognition mechanisms of Epstein-Barr Virus antigens by adaptive NK cells expressing activating receptors KIR (July 1, 2024 — June 30, 2027). Streltsova M.A.. Grant, RSF.